論文（査読あり）

1)      Yanagita E, Yamada H, Kobayashi T, Aimono E, Nakamura K, Hirasawa A, Nishihara H. The DNA integrity number and concentration are useful parameters for successful comprehensive genomic profiling test for cancer using formalin-fixed paraffin embedded tissue. First published: 27 March 2023.  Published Online https://doi.org/10.1111/pin.13318.

2)      Okada Y. Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T. Okudela K, Okuzaki D, Motooka D, Kanai M. Naito T, Yamamoto K, Wang Q, Saiki R, Ishihara R, Matsubara Y, Ogawa T, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E. Okada Y. et al.  DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature 609: 754–760 (2022).

3)      Uwamino Y, Wakui M, Aoki W, Kurafuji T, Yanagita E, Morita M, Nagata M, Inose R, Noguchi M, Yokota H, Hasegawa N, Saya H, Murata M; Keio Donner Project Team (2021). Evaluation of the usability of various rapid antibody tests in the diagnostic application for COVID-19. Ann Clin Biochem. 58(3):174-180. DOI: 10.1177/0004563220984827.

4)      Hayashi H, Tanishima S, Fujii K, Mori R, Okada C, Yanagita E, Shibata Y, Matsuoka R, Amano T, Yamada T, Yabe I, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H (2020). Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. Cancer Sci. 111(10):3926-3937. DOI: 10.1111/cas.14608.

5)      Machinaga A, Hori Y, Shimizu K, Okahara K, Yanagita E, Miyoshi M, Itoh T, Sasai K (2019). Xenografts derived from patients’ ascites recapitulate the gemcitabine resistance observed in pancreatic cancer patients. Pancreas. 48(10):1294-1302. DOI: 10.1097/MPA.0000000000001438.

6)      Yanagita E, Yamada H, Matsuoka R, Kato Y, Aimono E, Nishihara H (2019). Current status and Issues in reporting the results of cancer genome medicine, Journal of Chromosome and Gene Analysis.  37(1):38-50. J-GLOBAL ID：201902227827341759

7)      Hayashi H, Tanishima S, Fujii K, Mori R, Okamura Y, Yanagita E, Matsuoka R, Amano T, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H (2018). Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology. 18(6):647-654. doi: 10.1016/j.pan.2018.07.006.

8)      Yanagita E, Nishihara H (2018). Roles of clinical laboratory technicians in cancer genomic medicine. The official journal of Japanese Society of Laboratory Medicine.  66 (5), 479-489. NII ID:40021584292

9)      Yanagita E, Nishihara H (2017). Promotion of personalized cancer care based on comprehensive cancer gene analysis. Modern Medical Laboratory, 45 (12), 1310-1314. DOI:10.11477/mf.1543207003

10)     Yanagita E, Nishihara H (2017). Promotion of personalized cancer care based on comprehensive cancer gene analysis, Modern Medical Laboratory. 45 (12), 1310-1314. DOI:10.11477/mf.1543207003

11)     Yanagita E, Yamada H, Matsuoka R, Itoh T (2017). Double immunohistochemical technique useful for differential diagnosis of mycosis fungoides. Japanese Journal of Medical Technoliry. 66 (3), 248-254. DOI:10.14932/jamt.16-68

12)     Sasai K, Takao-Rikitsu E, Sukezane T, Yanagita E, Nakagawa H, Itoh-Yagi M, Izumi Y, Itoh T, Akagi T (2017). Engineering cancer stem-like cells from normal human lung epithelial cells. PLoS One. 12(4):e0175147. DOIi: 10.1371/journal.pone.0175147. PMID: 28380052

13)     Ueda Y, Takahashi S, Ohno N, Kyotani K, Kawamitu H, Miyati T, Aoyama N, Ueno Y, Kitajima K, Kawakami F, Okuaki T, Tsukamoto R, Yanagita E, Sugimura K (2016). Triexponential function analysis of diffusion-weighted MRI for diagnosing prostate cancer. J Magn Reson Imaging. 2016 Jan;43(1):138-48. DOI: 10.1002/jmri.24974.PMID: 26119033

14)     Shimakata T, Kamoshida S, Kawamura J, Ogane N, Kameda Y, Yanagita E, Itoh T, Takeda R, Naka A, Sakamaki K, Hayashi Y, Kuwao S (2016). Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer. Histopathology. 69(5):812-821. doi: 10.1111/his.13004. PMID: 27245475

15)     Tauchi S, Sakai Y, Fujimoto S, Ogawa H, Tane S, Hokka D, Tanaka Y, Nishio W, Yoshimura M, Yanagita E, Itoh T, Hayashi Y, Maniwa Y (2016). Psf3 is a prognostic biomarker in lung adenocarcinoma: a larger trial using tissue microarrays of 864 consecutive resections. Eur J Cardiothorac Surg. 50(4):758-764. DOI: 10.1093/ejcts/ezw077. PMID: 27005977

16)     Tomono A, Itoh T, Yanagita E, Imagawa N, Kakeji Y (2015). Cell cycle kinetic analysis of colorectal neoplasms using a new automated immunohistochemistry-based cell cycle detection method. Medicine (Baltimore). 94(4): e501. DOI: 10.1097/MD.0000000000000501.PMID: 25634203

17)     Watanabe D, Ooi M, Hoshi N, Kohashi M, Yoshie T, Ikehara N, Yoshida M, Yanagita E, Yamasaki T, Itoh T, Azuma T (2014). Successful treatment of Cronkhite-Canada syndrome using anti-tumor necrosis factor antibody therapy. Endoscopy. Suppl 1 UCTN:E476-7. DOI: 10.1055/s-0034-1377539. PMID: 25314205

18)     Sakai Y, Nakai T, Ohbayashi C, Imagawa N, Yanagita E, Satake R, Nitta A, Kajimoto K, Sakuma T, Itoh T (2013). Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. Int J Surg Pathol. 21(5):476-82. DOI: 10.1177/1066896913489345. PMID: 23794492

19)     Yanagita E, Kamoshida S, Imagawa N, Itoh T (2012). Immunohistochemistry-based cell cycle detection (iCCD): a novel system to visualize cell kinetics on formalin-fixed paraffin-embedded tissues. Am J Surg Pathol. 36(5):769-73. DOI: 10.1097/PAS.0b013e3182478b93.PMID: 22498826

20)     Kawanabe N, Murata S, Fukushima H, Ishihara Y, Yanagita T, Yanagita E, Ono M, Kurosaka H, Kamioka H, Itoh T, Kuboki T, Yamashiro T (2012). Stage-specific embryonic antigen-4 identifies human dental pulp stem cells. Exp Cell Res. 318(5):453-63. DOI: 10.1016/j.yexcr.2012.01.008. PMID: 22266579

21)     Yanagita E, Imagawa N, Ohbayashi C, Itoh T (2011). Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Appl Immunohistochem Mol Morphol. 19(6):509-13. DOI: 10.1097/PAI.0b013e318212f027.PMID: 21415705

22)     Yanagita E, Imagawa N, Obayashi C, Itoh T (2011).  Multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Applied Immunohistochemistry & Molecular Morphology. 19(6):509-13. DOI:10.1097 / PAI.0b013e318212f027

23)     Sasai K, Sukezane T, Yanagita E, Nakagawa H, Hotta A, Itoh T, Akagi T (2011). Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo. Cancer Res. 71(7):2541-9. DOI: 10.1158/0008-5472.CAN-10-2221. PMID: 21447735

24)     Yanagita E, Itoh T (2010). Evaluation of IgG4/IgG ratio in IgG4-related sclerosing disease using the masking double immunostaining method. Pathology and Clinical Medicine. 28(9),986-991. J-GLOBAL ID：201002285246412135

25)     Yanagita E, Itoh T (2010). Immunomultiplex staining protocols with commercial kits. Pathology and Clinical Medicine.  28(1), 91-95. J-GLOBAL ID：201002273664414553

26)     Abdel-Daim M, Funasaka Y, Kamo T, Ooe M, Matsunaka H, Yanagita E, Itoh T, Nishigori C (2010). Effect of chemical peeling on photocarcinogenesis. J Dermatol. 37(10):864-72. DOI: 10.1111/j.1346-8138.2010.00859.x.PMID: 20860736

27)     Wakahashi K, Shimoyama M, Katayama Y, Minagawa K, Yoshida K, Sasaki R, Nakayama S, Yokozaki H, Yanagita E, Itoh T, Hayashi Y, Matsui T (2010). Histiocytic sarcoma with two immunohistopathologically distinct populations. Int J Hematol.92(4):642-6. doi: 10.1007/s12185-010-0699-1. PMID: 20924729

28)     Abdel-Daim M, Funasaka Y, Komoto M, Nakagawa Y, Yanagita E, Nishigori C (2010). Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation. J Dermatol. 37(7):635-46. DOI: 10.1111/j.1346-8138.2010.00833.x.PMID: 20629830

29)     Abdel-Daim M, Funasaka Y, Kamo T, Ooe M, Matsunaka H, Yanagita E, Itoh T, Nishigori C (2010). Preventive effect of chemical peeling on ultraviolet induced skin tumor formation. J Dermatol Sci. 60(1):21-8. DOI: 10.1016/j.jdermsci.2010.08.002. PMID: 20832250

学会発表（Internationalのみ）

・A novel method to evaluate cell cycle kinetics using multi colored immunohistochemistry on the paraffin sections.  International Academy of Pathology, Hong Kong Division meeting (2010).

・Support of pathological technological technology and international exchange in Nepal. The 32nd World Congress of Biomedical Laboratory Science（IFBLS2016）

・Depeloping techniques for differenting between clear cell adenocarcinoma and serous adenocarcinoma in ovary. The 32nd World Congress of Biomedical Laboratory Science（IFBLS2016）.

・Depeloping techniques for differentiating between melanoma and spitz by using iCCD. The 32nd World Congress of Biomedical Laboratory Science（IFBLS2016）.

・Depeloping techniques for differentiating between squamous cell carcinoma and keratoacanthoma by using iCCD. (The 32nd World Congress of Biomedical Laboratory Science.（IFBLS2016）

・To make multiplex immunohistochemistry more efficient and quicker in Electric Field Non-Contact Techniques. The 32nd World Congress of Biomedical Laboratory Science（IFBLS2016）.

・Establishment of New Staining Protocols for Computational Pathology.  PI Summit 2024 / Detroit, USA.2024

・Establishment of New Criteria for Automated HER2 RNA ISH Assessment. USCAP 2025 / Boston,USA. 2025

特許
Rapid and sensitive multiplex immunostaining method （Patent Number：JP6421369）